Department of Chemical and Biomedical Engineering, Cleveland State University, 455 Fenn Hall (FH), 1960 East 24th Street, Cleveland, OH, 44115-2214, USA.
Compound Safety Prediction, Pfizer Inc., Groton, CT, 06340, USA.
Arch Toxicol. 2018 Mar;92(3):1295-1310. doi: 10.1007/s00204-017-2126-3. Epub 2017 Nov 22.
Human liver contains various oxidative and conjugative enzymes that can convert nontoxic parent compounds to toxic metabolites or, conversely, toxic parent compounds to nontoxic metabolites. Unlike primary hepatocytes, which contain myriad drug-metabolizing enzymes (DMEs), but are difficult to culture and maintain physiological levels of DMEs, immortalized hepatic cell lines used in predictive toxicity assays are easy to culture, but lack the ability to metabolize compounds. To address this limitation and predict metabolism-induced hepatotoxicity in high-throughput, we developed an advanced miniaturized three-dimensional (3D) cell culture array (DataChip 2.0) and an advanced metabolizing enzyme microarray (MetaChip 2.0). The DataChip is a functionalized micropillar chip that supports the Hep3B human hepatoma cell line in a 3D microarray format. The MetaChip is a microwell chip containing immobilized DMEs found in the human liver. As a proof of concept for generating compound metabolites in situ on the chip and rapidly assessing their toxicity, 22 model compounds were dispensed into the MetaChip and sandwiched with the DataChip. The IC values obtained from the chip platform were correlated with rat LD values, human C values, and drug-induced liver injury categories to predict adverse drug reactions in vivo. As a result, the platform had 100% sensitivity, 86% specificity, and 93% overall predictivity at optimum cutoffs of IC and C values. Therefore, the DataChip/MetaChip platform could be used as a high-throughput, early stage, microscale alternative to conventional in vitro multi-well plate platforms and provide a rapid and inexpensive assessment of metabolism-induced toxicity at early phases of drug development.
人类肝脏含有各种氧化和结合酶,可将无毒的母体化合物转化为有毒的代谢物,或者相反,将有毒的母体化合物转化为无毒的代谢物。与含有多种药物代谢酶(DME)但难以培养且难以维持 DME 生理水平的原代肝细胞不同,用于预测毒性测定的永生化肝细胞系易于培养,但缺乏代谢化合物的能力。为了解决这一限制并在高通量中预测代谢诱导的肝毒性,我们开发了先进的微型化三维(3D)细胞培养阵列(DataChip 2.0)和先进的代谢酶微阵列(MetaChip 2.0)。DataChip 是一种功能化微柱芯片,可支持 Hep3B 人肝癌细胞系以 3D 微阵列格式存在。MetaChip 是一种含有固定化 DME 的微孔芯片,这些 DME 存在于人类肝脏中。作为在芯片上原位生成化合物代谢物并快速评估其毒性的概念验证,将 22 种模型化合物分配到 MetaChip 中,并与 DataChip 夹在一起。从芯片平台获得的 IC 值与大鼠 LD 值、人体 C 值和药物诱导的肝损伤类别相关联,以预测体内的不良反应。结果,该平台在最佳 IC 值和 C 值截止值下具有 100%的灵敏度、86%的特异性和 93%的总体预测性。因此,DataChip/MetaChip 平台可用作高通量、早期、微尺度的替代传统的体外多孔板平台,并可在药物开发的早期阶段快速且廉价地评估代谢诱导的毒性。